financetom
Business
financetom
/
Business
/
ICICI Bank may appoint new chairman by month-end, says report
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ICICI Bank may appoint new chairman by month-end, says report
Jun 27, 2018 1:18 AM

Fraud-hit private lender ICICI Bank may appoint new chairman by the end of the month as current chairman MK Sharma's term ends on June 30, reported The Hindu BusinessLine.

A decision is expected at the next meeting of the board of directors of ICICI Bank this week, the daily said, adding that Sharma is understood to have indicated that he does not wish to continue.

The former Bank of Baroda chairman and managing director MD Mallya is the top contender for the post and he is understood to be the top choice of most directors, the report said.

The board of ICICI Bank has also been in contact with the Reserve Bank of India for its approval, the report added.

However, Mallya, along with five other former officials of Bank of Baroda, was questioned CBI with regard to the Rs 2,919 crore alleged loan fraud by Rotomac.

“This is the only issue, which could pose a problem with foreign investors. Otherwise Mallya is the top choice,” a source familiar with the development was quoted as saying in the report.

The bank is also looking to induct fresh people on the board, who can later serve as the non-executive chairman of ICICI Bank, HBL said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Mar 5, 2024
Immutep Limited ( IMMP ) announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha (efti) in combination with weekly paclitaxel in patients from the safety lead-in (N=6) of the AIPAC-003 Phase 2/3 trial. Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events. ...
Campbell Soup Positioned For Largely In-Line Second Quarter, RBC Says
Campbell Soup Positioned For Largely In-Line Second Quarter, RBC Says
Mar 5, 2024
04:02 PM EST, 03/05/2024 (MT Newswires) -- Campbell Soup ( CPB ) is positioned for a largely in-line fiscal second quarter with possible top-line upside amid strong January soup trends, though the consumer packaged food industry remains challenged, RBC Capital Markets said Tuesday. Campbell's salty snacks category continues to slow and its soup business faces pressure from a trade-down to...
Berkshire's PacifiCorp ordered to pay $29.2 million to homeowners, summer camp for 2020 Oregon wildfire damage
Berkshire's PacifiCorp ordered to pay $29.2 million to homeowners, summer camp for 2020 Oregon wildfire damage
Mar 5, 2024
(Reuters) - An Oregon state jury on Tuesday ordered Berkshire Hathaway's ( BRK/A ) PacifiCorp ( PPWLM ) to pay at least $29.2 million to nine homeowners and a summer camp whose properties were damaged by 2020 wildfires they claim were sparked when the Oregon utility failed to shut off its power lines during high winds. The verdict came in...
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
Mar 5, 2024
04:04 PM EST, 03/05/2024 (MT Newswires) -- Nektar Therapeutics ( NKTR ) said Tuesday it started the phase 2b trial for rezpegaldesleukin to treat patients experiencing severe to very severe alopecia areata. The Phase 2b study will evaluate rezpegaldesleukin's efficacy and safety in 84 participants with severe alopecia areata over a 36-week period using a randomized, double-blind, placebo-controlled dosage, Nektar...
Copyright 2023-2025 - www.financetom.com All Rights Reserved